New Quality Control Reference for Monitoring NGS-Based Tumor Profiling Assays
By LabMedica International staff writers Posted on 20 Jul 2015 |
Image: The Seraseq Solid Tumor Mutation Mix kit (Photo courtesy of SeraCare).
A newly released kit was designed to enable genomics researchers and drug developers to evaluate the performance of next generation sequencing (NGS)-based tumor profiling assays.
The SeraCare Life Sciences (Milford, MA, USA) Seraseq Solid Tumor Mutation Mix-I reference material is a mixture of biosynthetic target genes with specific engineered mutations in a wild-type background of well-characterized genomic DNA and is compatible with all major cancer hotspot oncology panels and NGS platforms on the market today. The reference matrix contains a mixture of mutations in key oncogenes and tumor suppressor genes and is intended as a quality control standard for translational and disease research testing.
This "for research use only" version includes 26 major cancer hotspot genes, all at 20% allelic frequency and quantified using digital PCR to ensure highest accuracy. The material is stable for two years under recommended storage conditions, and can undergo ten freeze-thaw cycles without any degradation of performance.
"SeraCare's extensive background and experience with the manufacture of quality reference and validation materials under cGMP ISO standards has enabled us to develop the Seraseq Solid Tumor Mutation Mix," said Dr. Russell Garlick, CSO at SeraCare. "This technology allows almost unlimited breadth of mutations and can be accurately "tuned" to specific allelic frequencies because we have incorporated digital PCR in the manufacturing. With this product, we can partner with in vitro diagnostics developers and clinical labs to offer a powerful performance tracking tool for their NGS tumor profiling assays."
Related Links:
SeraCare Life Sciences
The SeraCare Life Sciences (Milford, MA, USA) Seraseq Solid Tumor Mutation Mix-I reference material is a mixture of biosynthetic target genes with specific engineered mutations in a wild-type background of well-characterized genomic DNA and is compatible with all major cancer hotspot oncology panels and NGS platforms on the market today. The reference matrix contains a mixture of mutations in key oncogenes and tumor suppressor genes and is intended as a quality control standard for translational and disease research testing.
This "for research use only" version includes 26 major cancer hotspot genes, all at 20% allelic frequency and quantified using digital PCR to ensure highest accuracy. The material is stable for two years under recommended storage conditions, and can undergo ten freeze-thaw cycles without any degradation of performance.
"SeraCare's extensive background and experience with the manufacture of quality reference and validation materials under cGMP ISO standards has enabled us to develop the Seraseq Solid Tumor Mutation Mix," said Dr. Russell Garlick, CSO at SeraCare. "This technology allows almost unlimited breadth of mutations and can be accurately "tuned" to specific allelic frequencies because we have incorporated digital PCR in the manufacturing. With this product, we can partner with in vitro diagnostics developers and clinical labs to offer a powerful performance tracking tool for their NGS tumor profiling assays."
Related Links:
SeraCare Life Sciences
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples